Nabriva Therapeutics Ownership 2024 | Who Owns Nabriva Therapeutics Now?

Overview ForecastChart

Institutional Ownership

0.00%

Insider Ownership

0.97%

Retail Ownership

99.03%

Institutional Holders

1.00

Nabriva Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VALUES FIRST ADVISORS, INC.	0.99%	0.03%	26,682	814	3.15%	46,610,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.87%	0.00%	23,361	300	1.30%	41,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	0.63%	0.00%	17,025	-	-	29,741,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.43%	-	11,607	11,607	100.00%	20,080,000	Mar 31, 2023
MORGAN STANLEY	0.15%	-	4,108	-330	-7.44%	7,176,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.07%	-	2,008	8	0.40%	3,214,000	Mar 31, 2023
UBS GROUP AG	0.05%	-	1,315	323	32.56%	2,297,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	346,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	84	-8	-8.70%	147,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	40	35	700.00%	70,000	Mar 31, 2023
ADDISON ADVISORS LLC	0.00%	-	8	-	-	14,000	Mar 31, 2023
IFP ADVISORS, INC	-	-	-	-28	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-22,294	-100.00%	-	Mar 31, 2023

Nabriva Therapeutics's largest institutional shareholder is VALUES FIRST ADVISORS, INC., holding 0.99% of the company's total share outstanding, currently valued at $46.61M. The top 10 institutional shareholders own together 3.22% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VALUES FIRST ADVISORS, INC.	0.99%	0.03%	26,682	814	3.15%	46,610,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	0.63%	0.00%	17,025	-	-	29,741,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.87%	0.00%	23,361	300	1.30%	41,000	Mar 31, 2023
ADDISON ADVISORS LLC	0.00%	-	8	-	-	14,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.07%	-	2,008	8	0.40%	3,214,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.43%	-	11,607	11,607	100.00%	20,080,000	Mar 31, 2023
UBS GROUP AG	0.05%	-	1,315	323	32.56%	2,297,000	Mar 31, 2023
MORGAN STANLEY	0.15%	-	4,108	-330	-7.44%	7,176,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	346,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	40	35	700.00%	70,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	84	-8	-8.70%	147,000	Mar 31, 2023
IFP ADVISORS, INC	-	-	-	-28	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-22,294	-100.00%	-	Mar 31, 2023

The largest Nabriva Therapeutics shareholder by % of total assets is VALUES FIRST ADVISORS, INC.. The company owns 26.68K shares of Nabriva Therapeutics (NBRV), representing 0.03% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	0.43%	-	11,607	11,607	100.00%	20,080,000	Mar 31, 2023
VALUES FIRST ADVISORS, INC.	0.99%	0.03%	26,682	814	3.15%	46,610,000	Mar 31, 2023
UBS GROUP AG	0.05%	-	1,315	323	32.56%	2,297,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.87%	0.00%	23,361	300	1.30%	41,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	346,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	40	35	700.00%	70,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.07%	-	2,008	8	0.40%	3,214,000	Mar 31, 2023
ADDISON ADVISORS LLC	0.00%	-	8	-	-	14,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	0.63%	0.00%	17,025	-	-	29,741,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	84	-8	-8.70%	147,000	Mar 31, 2023
IFP ADVISORS, INC	-	-	-	-28	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	0.15%	-	4,108	-330	-7.44%	7,176,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-22,294	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Nabriva Therapeutics's largest institutional buyer is CITADEL ADVISORS LLC. The company purchased 11.61K stocks of NBRV, valued at $20.08M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-22,294	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	0.15%	-	4,108	-330	-7.44%	7,176,000	Mar 31, 2023
IFP ADVISORS, INC	-	-	-	-28	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	84	-8	-8.70%	147,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	0.63%	0.00%	17,025	-	-	29,741,000	Mar 31, 2023
ADDISON ADVISORS LLC	0.00%	-	8	-	-	14,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.07%	-	2,008	8	0.40%	3,214,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	40	35	700.00%	70,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	346,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.87%	0.00%	23,361	300	1.30%	41,000	Mar 31, 2023
UBS GROUP AG	0.05%	-	1,315	323	32.56%	2,297,000	Mar 31, 2023
VALUES FIRST ADVISORS, INC.	0.99%	0.03%	26,682	814	3.15%	46,610,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.43%	-	11,607	11,607	100.00%	20,080,000	Mar 31, 2023

As of Mar 31 2023, Nabriva Therapeutics's biggest institutional seller is SUSQUEHANNA INTERNATIONAL GROUP, LLP. The company sold -22.29K shares of NBRV, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	0.43%	-	11,607	11,607	100.00%	20,080,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	346,000	Mar 31, 2023

Nabriva Therapeutics's largest new institutional shareholder by number of shares is CITADEL ADVISORS LLC, purchased 11.61K shares, valued at $20.08M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-22,294	-100.00%	-	Mar 31, 2023
IFP ADVISORS, INC	-	-	-	-28	-100.00%	-	Mar 31, 2023

Nabriva Therapeutics's largest sold out institutional shareholder by shares sold is SUSQUEHANNA INTERNATIONAL GROUP, LLP, sold -22.29K shares, valued at -, as of undefined.

Nabriva Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
ALLSPRING MASTER TRUST	0.00%	7,024	-	-	Feb 29, 2024

Nabriva Therapeutics's largest mutual fund holder by % of total assets is "ALLSPRING MASTER TRUST", owning 7.02K shares, compromising 0.00% of its total assets.

Nabriva Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 22	1	-
31 Mar, 22	1	-
31 Dec, 21	1	-
30 Sep, 21	1	-
30 Jun, 21	1	-
31 Mar, 21	1	-50.00%
31 Dec, 20	2	-95.92%
30 Sep, 20	49	-7.55%
30 Jun, 20	53	3.92%
31 Mar, 20	51	4.08%
31 Dec, 19	49	4.26%
30 Sep, 19	47	11.90%
30 Jun, 19	42	2.44%
31 Mar, 19	41	-12.77%
31 Dec, 18	47	2.17%
30 Sep, 18	46	4.55%
30 Jun, 18	44	-6.38%
31 Mar, 18	47	6.82%
31 Dec, 17	44	10.00%
30 Sep, 17	40	100.00%
30 Jun, 17	20	-

As of 30 Jun 22, 1 institutions are holding Nabriva Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 22	3,000	-40.00%
31 Mar, 22	5,000	-
31 Dec, 21	5,000	-
30 Sep, 21	5,000	-
30 Jun, 21	5,000	-
31 Mar, 21	5,000	-97.45%
31 Dec, 20	196,028	-99.46%
30 Sep, 20	36,083,089	-3.59%
30 Jun, 20	37,425,269	61.37%
31 Mar, 20	23,191,892	-6.04%
31 Dec, 19	24,681,793	6.34%
30 Sep, 19	23,210,347	-18.49%
30 Jun, 19	28,475,895	-2.14%
31 Mar, 19	29,099,267	-9.51%
31 Dec, 18	32,156,943	1.02%
30 Sep, 18	31,831,886	51.46%
30 Jun, 18	21,016,538	-16.74%
31 Mar, 18	25,241,375	12.34%
31 Dec, 17	22,469,354	6.82%
30 Sep, 17	21,034,565	66.91%
30 Jun, 17	12,602,491	-

Nabriva Therapeutics (NBRV) has 3.00K shares outstanding as of 30 Jun 22, down -40.00% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 22	0.00%	6562.35%
31 Mar, 22	0.01%	10485.56%
31 Dec, 21	0.01%	9197.98%
30 Sep, 21	0.01%	6528.46%
30 Jun, 21	0.01%	3444.44%
31 Mar, 21	0.02%	1.28%
31 Dec, 20	1.22%	0.20%
30 Sep, 20	24.94%	2.26%
30 Jun, 20	33.18%	5.52%
31 Mar, 20	24.52%	2.59%
31 Dec, 19	30.75%	3.22%
30 Sep, 19	30.88%	2.00%
30 Jun, 19	39.26%	2.19%
31 Mar, 19	42.36%	1.06%
31 Dec, 18	63.31%	2.13%
30 Sep, 18	54.47%	2.02%
30 Jun, 18	51.87%	1.11%
31 Mar, 18	68.38%	1.21%
31 Dec, 17	75.32%	1.35%
30 Sep, 17	74.73%	3.48%
30 Jun, 17	46.36%	-

As of 30 Jun 22, Nabriva Therapeutics is held by 0.00% institutional shareholders, representing a 6562.35% growth compared to 31 Mar 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 22	-	-
31 Mar, 22	-	-
31 Dec, 21	-	-
30 Sep, 21	-	-
30 Jun, 21	-	-
31 Mar, 21	-	-
31 Dec, 20	-	-100.00%
30 Sep, 20	21	-16.00%
30 Jun, 20	25	13.64%
31 Mar, 20	22	-4.35%
31 Dec, 19	23	-17.86%
30 Sep, 19	28	55.56%
30 Jun, 19	18	-
31 Mar, 19	18	-5.26%
31 Dec, 18	19	-32.14%
30 Sep, 18	28	21.74%
30 Jun, 18	23	53.33%
31 Mar, 18	15	-44.44%
31 Dec, 17	27	-22.86%
30 Sep, 17	35	75.00%
30 Jun, 17	20	-

- institutional shareholders have increased their position in NBRV stock as of 30 Jun 22 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 22	1	-
31 Mar, 22	-	-
31 Dec, 21	-	-
30 Sep, 21	-	-
30 Jun, 21	-	-
31 Mar, 21	-	-100.00%
31 Dec, 20	2	-66.67%
30 Sep, 20	6	-14.29%
30 Jun, 20	7	-41.67%
31 Mar, 20	12	33.33%
31 Dec, 19	9	80.00%
30 Sep, 19	5	-37.50%
30 Jun, 19	8	-
31 Mar, 19	8	-46.67%
31 Dec, 18	15	36.36%
30 Sep, 18	11	10.00%
30 Jun, 18	10	-44.44%
31 Mar, 18	18	260.00%
31 Dec, 17	5	66.67%
30 Sep, 17	3	-
30 Jun, 17	-	-

1 institutional shareholders have reduced their position in NBRV stock as of 30 Jun 22 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 22	1	-	3,000	-40.00%	0.00%	6562.35%	-	-	1	-
31 Mar, 22	1	-	5,000	-	0.01%	10485.56%	-	-	-	-
31 Dec, 21	1	-	5,000	-	0.01%	9197.98%	-	-	-	-
30 Sep, 21	1	-	5,000	-	0.01%	6528.46%	-	-	-	-
30 Jun, 21	1	-	5,000	-	0.01%	3444.44%	-	-	-	-
31 Mar, 21	1	-50.00%	5,000	-97.45%	0.02%	1.28%	-	-	-	-100.00%
31 Dec, 20	2	-95.92%	196,028	-99.46%	1.22%	0.20%	-	-100.00%	2	-66.67%
30 Sep, 20	49	-7.55%	36,083,089	-3.59%	24.94%	2.26%	21	-16.00%	6	-14.29%
30 Jun, 20	53	3.92%	37,425,269	61.37%	33.18%	5.52%	25	13.64%	7	-41.67%
31 Mar, 20	51	4.08%	23,191,892	-6.04%	24.52%	2.59%	22	-4.35%	12	33.33%
31 Dec, 19	49	4.26%	24,681,793	6.34%	30.75%	3.22%	23	-17.86%	9	80.00%
30 Sep, 19	47	11.90%	23,210,347	-18.49%	30.88%	2.00%	28	55.56%	5	-37.50%
30 Jun, 19	42	2.44%	28,475,895	-2.14%	39.26%	2.19%	18	-	8	-
31 Mar, 19	41	-12.77%	29,099,267	-9.51%	42.36%	1.06%	18	-5.26%	8	-46.67%
31 Dec, 18	47	2.17%	32,156,943	1.02%	63.31%	2.13%	19	-32.14%	15	36.36%
30 Sep, 18	46	4.55%	31,831,886	51.46%	54.47%	2.02%	28	21.74%	11	10.00%
30 Jun, 18	44	-6.38%	21,016,538	-16.74%	51.87%	1.11%	23	53.33%	10	-44.44%
31 Mar, 18	47	6.82%	25,241,375	12.34%	68.38%	1.21%	15	-44.44%	18	260.00%
31 Dec, 17	44	10.00%	22,469,354	6.82%	75.32%	1.35%	27	-22.86%	5	66.67%
30 Sep, 17	40	100.00%	21,034,565	66.91%	74.73%	3.48%	35	75.00%	3	-
30 Jun, 17	20	-	12,602,491	-	46.36%	-	20	-	-	-

Nabriva Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 31, 2023	Gelone Steven P.	director	-	F-InKind	Sell	140	$1.50	$210.00	14,283
Jan 31, 2023	Schroeder Theodore R	director	-	F-InKind	Sell	431	$1.50	$646.50	11,989
Jan 10, 2023	Gelone Steven P.	officer	President and COO	F-InKind	Sell	5	$1.30	$6.50	14,423
Jan 10, 2023	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	11	$1.30	$14.30	12,420
Jan 04, 2023	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$1.89	$9.45	12,431
Jan 04, 2023	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$1.89	$5.67	14,428
Dec 08, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.02	$8.08	14,431
Dec 08, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	9	$2.02	$18.18	12,436
Dec 02, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.25	$6.75	14,435
Dec 02, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.25	$11.25	12,445
Nov 08, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.24	$8.96	14,438
Nov 08, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	10	$2.24	$22.39	12,450
Nov 01, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.54	$12.70	12,460
Nov 01, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.54	$7.62	14,442
Oct 11, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	9	$2.72	$24.48	12,465
Oct 11, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.72	$10.88	14,445
Oct 04, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.08	$6.24	14,449
Oct 04, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.08	$10.40	12,474

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 10, 2023	HOGAN H MICHAEL III	officer	-		Buy	-	-	-	-
Jul 10, 2023	Maggio David	officer	-		Buy	-	-	-	-
Jan 31, 2023	Gelone Steven P.	director	-	F-InKind	Sell	140	$1.50	$210.00	14,283
Jan 31, 2023	Schroeder Theodore R	director	-	F-InKind	Sell	431	$1.50	$646.50	11,989
Jan 10, 2023	Gelone Steven P.	officer	President and COO	F-InKind	Sell	5	$1.30	$6.50	14,423
Jan 10, 2023	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	11	$1.30	$14.30	12,420
Jan 04, 2023	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$1.89	$9.45	12,431
Jan 04, 2023	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$1.89	$5.67	14,428
Dec 08, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.02	$8.08	14,431
Dec 08, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	9	$2.02	$18.18	12,436
Dec 02, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.25	$6.75	14,435
Dec 02, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.25	$11.25	12,445
Nov 08, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.24	$8.96	14,438
Nov 08, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	10	$2.24	$22.39	12,450
Nov 01, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.54	$12.70	12,460
Nov 01, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.54	$7.62	14,442
Oct 11, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	9	$2.72	$24.48	12,465
Oct 11, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	4	$2.72	$10.88	14,445
Oct 04, 2022	Gelone Steven P.	officer	President and COO	F-InKind	Sell	3	$2.08	$6.24	14,449
Oct 04, 2022	Schroeder Theodore R	officer	Chief Executive Officer	F-InKind	Sell	5	$2.08	$10.40	12,474

The last insider sell of Nabriva Therapeutics's stock was made by Gelone Steven P. on Jan 31 2023, selling 140 shares at $1.50 per share (valued at $210.00).

Nabriva Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2023	-	4	-
Q4 2022	-	12	-
Q3 2022	3	21	14.29%
Q2 2022	-	12	-
Q1 2022	10	14	71.43%
Q4 2021	3	12	25.00%
Q3 2021	15	22	68.18%
Q2 2021	3	18	16.67%
Q1 2021	5	19	26.32%
Q4 2020	-	15	-
Q3 2020	18	29	62.07%
Q2 2020	-	18	-
Q1 2020	12	18	66.67%
Q3 2019	17	18	94.44%
Q1 2019	12	-	-
Q4 2018	1	-	-
Q3 2018	9	-	-
Q2 2018	14	-	-
Q1 2018	11	-	-
Q4 2017	1	-	-

0 total buy trades, and 4 total sell trades (buy/sell ratio of 0.00%) were made by Nabriva Therapeutics's insiders, as of Q1 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2023	-	-	-
Q4 2022	-	-	-
Q3 2022	-	6	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q4 2021	2	-	-
Q3 2021	1	5	20.00%
Q2 2021	-	-	-
Q1 2021	-	-	-
Q4 2020	-	-	-
Q3 2020	-	1	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q3 2019	3	6	50.00%
Q1 2019	-	-	-
Q4 2018	1	-	-
Q3 2018	2	-	-
Q2 2018	8	-	-
Q1 2018	-	-	-
Q4 2017	1	-	-

As of Q1 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Nabriva Therapeutics's stocks.

Nabriva Therapeutics Peer Ownership

Ticker	Company
EVOK	Evoke Pharma, Inc.
TRVN	Trevena, Inc.
DFFN	CervoMed Inc.
CLSD	Clearside Biomedical, Inc.

NBRV Ownership FAQ

Who Owns Nabriva Therapeutics?

Nabriva Therapeutics is owned by institutional shareholders (0.00%), insiders (0.97%), and public (99.03%). The largest institutional shareholder of Nabriva Therapeutics is VALUES FIRST ADVISORS, INC. (0.99% of total shares) and the top mutual fund owner is ALLSPRING MASTER TRUST (0.00% of total shares).

Who are the major institutional shareholders of Nabriva Therapeutics?

Nabriva Therapeutics's major institutional shareholders are VALUES FIRST ADVISORS, INC., RENAISSANCE TECHNOLOGIES LLC, FRAZIER LIFE SCIENCES MANAGEMENT, L.P., CITADEL ADVISORS LLC, and MORGAN STANLEY. The top five shareholders own together 3.09% of the company's share outstanding.

How many Nabriva Therapeutics shareholders are there?

As of Jun 2022, there are 1 institutional shareholders of Nabriva Therapeutics.

What percentage of Nabriva Therapeutics is owned by VALUES FIRST ADVISORS, INC?

VALUES FIRST ADVISORS, INC owns 26.68K shares of Nabriva Therapeutics, representing 0.99% of the company's total shares outstanding, valued at $46.61M (as of Mar 2023).

What percentage of Nabriva Therapeutics is owned by RENAISSANCE TECHNOLOGIES LLC?

As of Mar 2023, RENAISSANCE TECHNOLOGIES LLC holds 23.36K shares of Nabriva Therapeutics (NBRV), compromising 0.87% of the company, valued at $41K.

What percentage of Nabriva Therapeutics is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?

FRAZIER LIFE SCIENCES MANAGEMENT, L.P is the third largest holder of Nabriva Therapeutics. The company owns 17.02K of the company's shares outstanding (worth $29.74M).